Skip to main content
. Author manuscript; available in PMC: 2010 Aug 23.
Published in final edited form as: Arch Neurol. 2008 May 12;65(7):896–905. doi: 10.1001/archneur.2008.65.7.nct70006

Table 3.

Longitudinal Effect of Treatment on Cognitive Function

Measure Celecoxib vs Placebo
 Naproxen Sodium vs Placebo
β (95% Confidence Interval) P Value β (95% Confidence Interval) P Value
Global summary score −0.01 (−0.05 to 0.02) .47 − 0.05 (−0.09 to -0.01) .02
Adjusted 3MS-E score −0.32 (−0.62 to -0.02) .04 − 0.36 (−0.68 to -0.04) .03
GVF score −0.27 (−0.73 to 0.19) .24 − 0.54 (−1.01 to -0.07) .02
RBMT delayed recall score −0.09 (−0.32 to 0.15) .47 − 0.18 (−0.42 to 0.06) .14
BVMT-R delayed recall score 0.03 (−0.15 to 0.21) .75 − 0.12 (−0.31 to 0.07) .22
Adjusted HVLT-R trial 4 score 0.08 (−0.11 to 0.27) .4 − 0.10 (−0.30 to 0.10) .34
Digit Span score, forward −0.06 (−0.20 to 0.08) .42 − 0.04 (−0.19 to 0.10) .55
Digit Span score, backward 0.03 (−0.11 to 0.17) .67 − 0.11 (−0.26 to 0.03) .13

Abbreviations: BVMT-R, Brief Visuospatial Memory Test–Revised; GVF, generative verbal fluency; HVLT-R, Hopkins Verbal Learning Test–Revised; RBMT, Rivermead Behavioral Memory Test; 3MS-E, Modified Mini-Mental State Examination.